Epigenetics and microRNAs in preeclampsia

Clinical and Experimental Hypertension

Volumn 34, Issue 5, 2012, Pages 334-341

  Choudhury, Mahua ^a   Friedman, Jacob E ^a,b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; Epigenetics; Imprinted genes; MicroRNA; Preeclampsia; Pregnancy

Indexed keywords

MICRORNA;

ARTICLE; DNA METHYLATION; EPIGENETICS; FETUS DEVELOPMENT; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; PATHOGENESIS; PREECLAMPSIA; PREGNANCY COMPLICATION;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; MICRORNAS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84863948725     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.649931     Document Type: Article

References (123)

1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308:1592-1594.
2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785-799.
3. Filetti LC, Imudia AN, Al-Safi Z, Hobson DT, Awonuga AO, Bahado-Singh RO. New onset delayed postpartum preeclampsia: different disorders? J Matern Fetal Neonatal Med 2011. [Epub ahead of print]
4. Firoz T, Melnik T. Postpartum evaluation and long term implications. Best Pract Res Clin Obstet Gynaecol 2011; 25:549-561.
5. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag 2011; 7:467-474.
6. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010; 376:631-644.
7. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010; 5:173-192.
8. McMaster MT, Zhou Y, Fisher SJ. Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 2004; 24:540-547.
9. Page EW. The relation between hydatid moles, relative ischemia of the gravid uterus and the placental origin of eclampsia. Am J Obstet Gynecol 1939; 37:291-293.
10. Li HW, Tsao SW, Cheung AN. Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta 2002; 23:20-31.
11. Apel-Sarid L, Levy A, Holcberg G, Sheiner E. Term and preterm (<34 and <37 weeks gestation) placental pathologies associated with fetal growth restriction. Arch Gynecol Obstet 2010; 282:487-492.
12. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010; 37: 239-253.
13. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359: 673-674.
14. Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med 2004; 9:357-369.
15. Goldman-Wohl DS, Yagel S. Examination of distinct fetal and maternal molecular pathways suggests a mechanism for the development of preeclampsia. J Reprod Immunol 2007; 76:54-60.
16. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.
17. Aggarwal S, Dimri N, Tandon I, Agarwal S. Preeclampsia in north Indian women: The contribution of genetic polymorphisms. J Obstet Gynaecol Res 2011; 37:1335-1341.
18. Williams PJ, Broughton Pipkin F. The genetics of preeclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25:405-417.
19. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the promisse cohort. PLoS Med 2011; 8:e1001013.
20. Lukiw WJ, Zhao Y, Cui JG. An nf-kappab-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008; 283:31315-31322.
21. Pogue AI, Li YY, Cui JG, et al. Characterization of an nf-kappab-regulated, miRNA-146a-mediated downregulation of complement factor h (CFH) in metal-sulfatestressed human brain cells. J Inorg Biochem 2009; 103: 1591-1595.
22. Bell CG, Beck S. The epigenomic interface between genome and environment in common complex diseases. Brief Funct Genomics 2010; 9:477-485.
23. Robins JC, Marsit CJ, Padbury JF, Sharma SS. Endocrine disruptors, environmental oxygen, epigenetics and pregnancy. Front Biosci (Elite Ed) 2011; 3:690-700.
24. Pozharny Y, Lambertini L, Clunie G, Ferrara L, Lee MJ. Epigenetics in women's health care. Mt Sinai J Med 2010; 77:225-235.
25. Ainsworth HF, Unwin J, Jamison DL, Cordell HJ. Investigation of maternal effects, maternal-fetal interactions and parent-of-origin effects (imprinting), using mothers and their offspring. Genet Epidemiol 2011; 35:19-45.
26. Ahmed F. Epigenetics: tales of adversity. Nature 2010; 468:S20.
27. Haluskova J. Epigenetic studies in human diseases. Folia Biol (Praha) 2010; 56:83-96.
28. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009; 49: 243-263.
29. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 2004; 20:63-68.
30. Choudhury M, Friedman JE. Obesity: childhood obesitymethylate now, pay later? Nat Rev Endocrinol 2011; 7: 439-440.
31. Maccani MA, Marsit CJ. Epigenetics in the placenta. Am J Reprod Immunol 2009; 62:78-89.
32. Wilkins-Haug L. Epigenetics and assisted reproduction. Curr Opin Obstet Gynecol 2009; 21:201-206.
33. Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum Reprod Update 2011; 17:397-417.
34. Carter AM. Animal models of human placentation-a review. Placenta 2007; 28(Suppl A):S41-S47.
35. Rahnama F, Shafiei F, Gluckman PD, Mitchell MD, Lobie PE. Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 2006; 147: 5275-5283.
36. Serman L, Vlahovic M, Sijan M, et al. The impact of 5-azacytidine on placental weight, glycoprotein pattern and proliferating cell nuclear antigen expression in rat placenta. Placenta 2007; 28:803-811.
37. Lo YM, Patel P, Wainscoat JS, Sampietro M, Gillmer MD, Fleming KA. Prenatal sex determination by DNA amplification from maternal peripheral blood. Lancet 1989; 2: 1363-1365.
38. Zhong XY, Burk MR, Troeger C, Jackson LR, Holzgreve W, Hahn S. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. Prenat Diagn 2000; 20:795-798.
39. Hahn S, Rusterholz C, Hosli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011; 32(Suppl):S17-S20.
40. Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci 2001; 945:138-140.
41. Lo YM, Lau TK, Zhang J, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999; 45:1747-1751.
42. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999; 45:184-188.
43. Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YM. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 1998; 352:1904-1905.
44. Chelbi ST, Vaiman D. Genetic and epigenetic factors contribute to the onset of preeclampsia. Mol Cell Endocrinol 2008; 282:120-129.
45. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69:1-7.
46. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to preeclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981; 88:876-881.
47. Zhou Y, Bellingard V, Feng KT, McMaster M, Fisher SJ. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of ang2, plgf, and VEGF-c. Dev Biol 2003; 263:114-125.
48. Jauniaux E, Gulbis B, Burton GJ. Physiological implications of the materno-fetal oxygen gradient in human early pregnancy. Reprod Biomed Online 2003; 7:250-253.
49. Kingdom JC, Kaufmann P. Oxygen and placental vascular development. Adv Exp Med Biol 1999; 474:259-275.
50. Chelbi ST, Mondon F, Jammes H, et al. Expressional and epigenetic alterations of placental serine protease inhibitors: Serpina3 is a potential marker of preeclampsia. Hypertension 2007; 49:76-83.
51. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006; 195:40-49.
52. Wenger RH, Kvietikova I, Rolfs A, Camenisch G, Gassmann M. Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. Eur J Biochem 1998; 253: 771-777.
53. Rossler J, Stolze I, Frede S, et al. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. J Cell Biochem 2004; 93:153-161.
54. Yuen RK, Penaherrera MS, von Dadelszen P,McFadden DE, Robinson WP. DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur J Hum Genet 2010; 18: 1006-1012.
55. Higuchi T, Kanzaki H, Nakayama H, et al. Induction of tissue inhibitor of metalloproteinase 3 gene expression during in vitro decidualization of human endometrial stromal cells. Endocrinology 1995; 136:4973-4981.
56. Pang ZJ, Xing FQ. Expression profile of trophoblast invasionassociated genes in the pre-eclamptic placenta. Br J Biomed Sci 2003; 60:97-101.
57. Zilberman D. The human promoter methylome. Nat Genet 2007; 39:442-443.
58. Godbole G, Suman P, Gupta SK, Modi D. Decidualized endometrial stromal cell derived factors promote trophoblast invasion. Fertil Steril 2011; 95:1278-1283.
59. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407-415.
60. Agarwal I, Karumanchi SA. Preeclampsia and the antiangiogenic state. Pregnancy Hypertens 2011; 1:17-21.
61. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sflt-1)induces proteinuria. J Biol Chem 2003; 278:12605-12608.
62. Levine RJ,Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
63. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
64. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649.
65. Kim JY, Hwang JH, Zhou W, et al. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. Epigenetics 2009; 4:313-321.
66. Turunen MP, Yla-Herttuala S. Epigenetic regulation of key vascular genes and growth factors. Cardiovasc Res 2011; 90:441-446.
67. Tsui DW, Chan KC, Chim SS, et al. Quantitative aberrations of hypermethylated rassf1a gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn 2007; 27:1212-1218.
68. BellidoML, Radpour R, Lapaire O, et al.MALDI-TOF mass array analysis of rassf1a and serpinb5 methylation patterns in human placenta and plasma. Biol Reprod 2010; 82:745-750.
69. Zhao F, Wang J, Liu R, et al. Quantification and application of the placental epigenetic signature of the rassf1a gene in maternal plasma. Prenat Diagn 2010; 30:778-782.
70. Chim SS, Tong YK, Chiu RW, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci USA 2005; 102:14753-14758.
71. Papageorgiou EA, Fiegler H, Rakyan V, et al. Sites of differential DNA methylation between placenta and peripheral blood: molecular markers for noninvasive prenatal diagnosis of aneuploidies. Am J Pathol 2009; 174:1609-1618.
72. Braekke K, Ueland PM, Harsem NK, Karlsen A, Blomhoff R, Staff AC. Homocysteine, cysteine, and related metabolites in maternal and fetal plasma in preeclampsia. Pediatr Res 2007; 62:319-324.
73. Kulkarni A, Chavan-Gautam P, Mehendale S, Yadav H, Joshi S. Global DNA methylation patterns in placenta and its association with maternal hypertension in pre-eclampsia. DNA Cell Biol 2011; 30:79-84.
74. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 2010; 21:529-536.
75. Wen SW, Chen XK, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008; 198(45):e41-e47.
76. Gascoin-Lachambre G, Buffat C, Rebourcet R, et al. Cullins in human intra-uterine growth restriction: expressional and epigenetic alterations. Placenta 2010; 31:151-157.
77. Arai T, Kasper JS, Skaar JR, Ali SH, Takahashi C, DeCaprio JA. Targeted disruption of p185/cul7 gene results in abnormal vascular morphogenesis. Proc Natl Acad Sci USA 2003; 100:9855-9860.
78. Delaval K, Feil R. Epigenetic regulation of mammalian genomic imprinting. Curr Opin Genet Dev 2004; 14: 188-195.
79. Kacem S, Feil R. Chromatinmechanisms in genomic imprinting. Mamm Genome 2009; 20:544-556.
80. Ideraabdullah FY, Vigneau S, Bartolomei MS. Genomic imprinting mechanisms in mammals. Mutat Res 2008; 647:77-85.
81. Graves JA. Genomic imprinting, development and disease-is pre-eclampsia caused by a maternally imprinted gene? Reprod Fertil Dev 1998; 10:23-29.
82. Isles AR, Holland AJ. Imprinted genes and mother-offspring interactions. Early Hum Dev 2005; 81:73-77.
83. van DijkM, Drewlo S, Oudejans CB. Differential methylation of stox1 in human placenta. Epigenetics 2010; 5:736-742.
84. van Dijk M, Oudejans CB. Stox1: key player in trophoblast dysfunction underlying early onset preeclampsia with growth retardation. J Pregnancy 2011; 2011:521826.
85. Hatada I, Mukai T. Genomic imprinting of p57kip2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 1995; 11:204-206.
86. Matsuoka S, Thompson JS, Edwards MC, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57kip2, on chromosome 11p15. Proc Natl Acad Sci USA 1996; 93:3026-3030.
87. Kanayama N, Takahashi K, Matsuura T, et al. Deficiency in p57kip2 expression induces preeclampsia-like symptoms in mice. Mol Hum Reprod 2002; 8:1129-1135.
88. Rachmilewitz J, Gileadi O, Eldar-Geva T, Schneider T, de-Groot N, Hochberg A. Transcription of the H19 gene in differentiating cytotrophoblasts from human placenta. Mol Reprod Dev 1992; 32:196-202.
89. Gabory A, Ripoche MA, Yoshimizu T, Dandolo L. The h19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res 2006; 113:188-193.
90. Mitalipov SM. Genomic imprinting in primate embryos and embryonic stem cells. Reprod Fertil Dev 2006; 18:817-821.
91. Yu L, Chen M, Zhao D, et al. The H19 gene imprinting in normal pregnancy and pre-eclampsia. Placenta 2009; 30: 443-447.
92. Walsh C, Miller SJ, Flam F, Fisher RA, Ohlsson R. Paternally derived H19 is differentially expressed in malignant and nonmalignant trophoblast. Cancer Res 1995; 55:1111-1116.
93. Gao WL, Li D, Xiao ZX, et al. Detection of global DNA methylation and paternally imprinted h19 gene methylation in preeclamptic placentas. Hypertens Res 2011; 34:655-661.
94. Bourque DK, Avila L, Penaherrera M, von Dadelszen P, Robinson WP. Decreased placental methylation at the H19/IGF2 imprinting control region is associated with normotensive intrauterine growth restriction but not preeclampsia. Placenta 2010; 31:197-202.
95. Kimura AP, Liebhaber SA, Cooke NE. Epigenetic modifications at the human growth hormone locus predict distinct roles for histone acetylation and methylation in placental gene activation. Mol Endocrinol 2004; 18:1018-1032.
96. Morris AC, Beresford GW, Mooney MR, Boss JM. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 2002; 22:4781-4791.
97. Chuang HC, Chang CW, Chang GD, Yao TP, Chen H. Histone deacetylase 3 binds to and regulates the GCMA transcription factor. Nucleic Acids Res 2006; 34:1459-1469.
98. Torres-Padilla ME. Cell identity in the preimplantation mammalian embryo: An epigenetic perspective from the mouse. Hum Reprod 2008; 23:1246-1252.
99. Barad O, Meiri E, Avniel A, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 2004; 14:2486-2494.
100. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007; 61:24R-29R.
101. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9:435-443.
102. Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med 2009; 47:923-929.
103. Pineles BL, Romero R, Montenegro D, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 2007; 196(261):e261-e266.
104. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K,Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. AmJ Obstet Gynecol 2011; 204(178):e112-e121.
105. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011; 18:46-56.
106. Noack F, Ribbat-Idel J, Thorns C, et al. MiRNA expression profiling in formalin-fixed and paraffin-embedded placental tissue samples from pregnancies with severe preeclampsia. J Perinat Med 2011; 39:267-271.
107. Zhu XM, Han T, Sargent IL, Yin GW, Yao YQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol 2009; 200(661):e661-e667.
108. Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35:856-867.
109. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105:577-587.
110. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25:763-769.
111. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283: R29-R45.
112. Soleymanlou N, Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005; 90:4299-4308.
113. Zhang Y, Fei M, Xue G, et al. Elevated levels of hypoxiainducible microRNA-210 in preeclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med 2011. [Epub ahead of print]
114. Dai Y, Diao Z, Sun H, Li R, Qiu Z, Hu Y. MicroRNA- 155 is involved in the remodelling of human-trophoblastderived htr-8/svneo cells induced by lipopolysaccharides. Hum Reprod 2011; 26:1882-1891.
115. Zhang Y, Diao Z, Su L, et al. MicroRNA-155 contributes to preeclampsia by down-regulating cyr61. Am J Obstet Gynecol 2010; 202(466):e461-e467.
116. Wang S, Olson EN. Angiomirs-key regulators of angiogenesis. Curr Opin Genet Dev 2009; 19:205-211.
117. Alpini G, Glaser SS, Zhang JP, et al. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol 2011; 55:1339-1345.
118. Cheng W, Liu T, Jiang F, et al. MicroRNA-155 regulates angiotensin ii type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int J Mol Med 2011; 27:393-399.
119. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin ii pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52: 2682-2689.
120. Herse F, Dechend R, Harsem NK, et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007; 49:604-611.
121. Shojaati K, Causevic M, Kadereit B, et al. Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. Kidney Int 2004; 66:2322-2328.
122. Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res 2007; 100: 520-526.
123. Goyal R, Goyal D, Leitzke A, Gheorghe CP, Longo LD. Brain renin-angiotensin system: fetal epigenetic programming by maternal protein restriction during pregnancy. Reprod Sci 2010; 17:227-238.